APA (7th ed.) Citation

E, C., ML, D. S., A, D. C., C, N., M, M., & F, F. (2023). Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1. Pharmaceuticals (Basel, Switzerland), 16(12), . https://doi.org/10.3390/ph16121678

Chicago Style (17th ed.) Citation

E, Criscuolo, De Sciscio ML, De Cristofaro A, Nicoara C, Maccarrone M, and Fezza F. "Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1." Pharmaceuticals (Basel, Switzerland) 16, no. 12 (2023). https://doi.org/10.3390/ph16121678.

MLA (9th ed.) Citation

E, Criscuolo, et al. "Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1." Pharmaceuticals (Basel, Switzerland), vol. 16, no. 12, 2023, https://doi.org/10.3390/ph16121678.